Optimal therapy for severe pneumococcal community-acquired pneumonia

Intensive Care Medicine

Volumn 32, Issue 7, 2006, Pages 971-980

  Luján, Manel ^a   Gallego, Miguel ^a   Rello, Jordi ^b  

^a PARC TAULÍ HOSPITAL UNIVERSITARI   (Spain)

^b HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

Author keywords

Combination therapy; Discordant therapy; Pneumococcus; Pneumonia

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CEFACLOR; CEFEPIME; CEFOTAXIME; CEFPODOXIME; CEFTRIAXONE; CEFUROXIME; CEFUROXIME AXETIL; CEPHALOSPORIN DERIVATIVE; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; GATIFLOXACIN; GLYCOPEPTIDE; LEVOFLOXACIN; LINCOSAMIDE; LINEZOLID; MACROLIDE; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; BACTERIAL VIRULENCE; COMMUNITY ACQUIRED PNEUMONIA; DISEASE SEVERITY; HUMAN; IMMUNOMODULATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PNEUMONIA; REVIEW; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; HUMANS; INTENSIVE CARE UNITS; PNEUMONIA, PNEUMOCOCCAL; STREPTOCOCCUS PNEUMONIAE;

EID: 33745464336     PISSN: 03424642     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00134-006-0182-x     Document Type: Review

References (62)

1. Garibaldi RA (1985) Epidemiology of community-acquired respiratory tract infections in adults: incidence, aetiology and impact. Am J Med 78:32S-38S
2. Guest JF, Morris A (1997) Community-acquired pneumonia: the annual cost to the National Health Service in UK. Eur Resper J 10:1530-1534
3. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, Coley CM, Marrie TJ, Kapoor WN (1997) A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 336:243-250
4. Rello J, Bodi M, Mariscal D, Navarro M, Diaz E, Gallego M, Valles J (2003) Microbiological testing and outcome of patients with severe community-acquired pneumonia. Chest 123:174-180. DOI 10.1378/chest.123.1.174
5. Bodí M, Rodríguez A, Solé-Violán J, Gilavert MC, Garnacho J, Blanquer J, Jimenez J, de la Torre MV, Sirvent JM, Almirall J, Doblas A, Badía JR, García F, Mendia A, Jordá R, Bobillo F, Vallés J, Broch MJ, Carrasco N, Herranz MA, Rello J. for CAPUCI study investigators (2005) Antibiotic prescription for community-acquired pneumonia in the intensive care unit. Impact of adherence to IDSA guidelines on outcome. Clin Infect Dis 41:1709-171 DOI 10.1086/498119
6. Torres A, Serra-Batlles J, Ferrer A, Jimenez P, Celis R, Cobo E, Rodriguez-Roisin R (1991) Severe community-acquired pneumonia. Epidemiology and prognostic factors Am Rev Respir Dis 144:312-318
7. Musher D, Alexandraki I, Graviss E, Yanbeiy N, Eid A, Inderias L, Phan H, Solomon E (2000) Bacteremic and non-bacteremic pneumococcal pneumonia: a prospective study. Medicine 79:210-221
8. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, Reingold A, Cieslak PR, Pilishvili T, Jackson D, Facklam RR, Jorgensen JH, Schuchat A, Active Bacterial Core Surveillance of the Emerging Infections Program Network (2003) Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 348:1737-1746
9. Waterer GW, Quasney MW, Cantor RM, Wunderink RG (2001) Septic shock and respiratory failure in community-acquired pneumonia have different TNF polymorphism associations. Am J Respir Crit Care Med 163:1599-1604
10. Meehan TP, Fine MJ, Krumholz HM, Scinto JD, Galusha DH, Mockalis JT, Weber GF, Petrillo MK, Houck PM, Fine JM (1997) Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA 278:2080-2084
11. Laterre PF, Garber G, Levy H, Wunderink R, Kinasewitz GT, Sollet JP, Maki DG, Bates B, Yan SC, Dhainaut JF, PROWESS Clinical Evaluation Committee (2005) Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study. Crit Care Med 33:952-961. DOI 10.1097/01.CCM.0000162381.24074. D7
12. Lujan M, Gallego M, Fontanals D, Mariscal D, Rello J (2004) Prospective observational study of bacteremic pneumococcal pneumonia: Effect of discordant therapy on mortality. Crit Care Med 32:625-631. DOI: 10.1097/01.CCM.0000114817. 58194. BF
13. Baddour LM, Yu VL, Klugman KP, Feldman C, Ortqvist A, Rello J, Morris AJ, Luna CM, Snydman DR, Ko WC, Chedid MB, Hui DS, Andremont A, Chiou CC, International Pneumococcal Study Group (2004) Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 170:440-444. DOI 10.1164/rccm.200311-1578OC
14. Chow JW, Yu VL (1999) Combination antibiotic versus monotherapy for gram-negative bacteremia: a commentary. Int J Antimicrob Agents 11:7
15. American Thoracic Society (2001) Guidelines for the management of adults with community acquired pneumonia. Am J Respir Crit Care Med 163:1730-1754
16. Bartlett JG, Dowell SF, Mandell LA, File TM, Musher DM, Fine MJ (2000) Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis 31:347-382
17. British Thoracic Society (2001) BTS guidelines for the management of community-acquired pneumonia in adults. Thorax 56[Suppl 4]:1-64
18. Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, Lewis SA, Macfarlane JT (2003) Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 58:377-382. DOI 10.1136/thorax.58.5.377
19. Tighman RC, Finland M (1937) Clinical significance of bacteremia in pneumococcal pneumonia. Arch Intern Med 1937 59:602-619
20. Jacobs MR, Koornhof HJ, Robins-Browne RM, Stevenson CM, Vermaak ZA, Freiman I, Miller GB, Witcomb MA, Isaacson M, Ward JI, Austrian R (1978) Emergency of multiply resistant pneumococci. N Engl J Med 299:735-740
21. Magnusdottir AB, Hermansson A, Melhus A (2000) Experimental study of the virulence of Streptococcus pneumoniae with reduced susceptibility to penicillin. Int J Pediatr Otorhinolaryngol 55:1-9
22. Rieux V, Carbon C, Azoulay-Dupuis E (2001) Complex relationship between acquisition of beta-lactam resistance and loss of virulence in Streptococcus pneumoniae. J Infect Dis 184:66-72
23. Azoulay-Dupuis E, Rieux V, Muffat-Joly M, Bedos JP, Vallee E, Rivier C, Isturiz R, Carbon C, Moine P (2000) Relationship between capsular type, penicillin susceptibility, and virulence of human Streptococcus pneumoniae isolates in mice. Antimicrob Agents Chemother 44:1575-1577
24. Aspa J, Rajas O, Rodriguez de Castro F, Blanquer J, Zalacain R, Fenoll A, de Celis R, Vargas A, Rodriguez Salvanes F, Espana PP, Rello J, Torres A; Pneumococcal Pneumonia in Spain Study Group (2004) Drug-resistant pneumococcal pneumonia: clinical relevance and related factors. Clin Infect Dis 38:787-798
25. Clavo-Sanchez AJ, Giron-Gonzalez JA, Lopez-Prieto D (1997) Multivariate analysis of risk factors for infection due to penicillin-resistant and multidrug-resistant Streptococcus pneumoniae: a multicenter study. Clin Infect Dis 24:1052-1059
26. Winston LG, Perlman JL, Rose DA, Gerberding JL (1999) Penicillin-nonsusceptible Streptococcus pneumoniae at San Francisco General Hospital. Clin Infect Dis 29:580-585
27. Pallares R, Linares J, Vadillo M, Cabellos C, Manresa F, Viladrich PF, Martin R, Gudiol F (1995) Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 333:474-480
28. Ewig S, Ruiz M, Torres A, Marco F, Martinez JA, Sanchez M, Mensa J (1999) Pneumonia acquired in the community through drug-resistant Streptococcus pneumoniae. Am J Respir Crit Care Med 159:1835-1842
29. Martinez JA, Horcajada JP, Almela M, Marco F, Soriano A, Garcia E, Marco MA, Torres A, Mensa J (2003) Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 36:389-385
30. Metlay JP, Hoffman J, Cetron MS (2000) Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 90:520-528
31. Musher DM, Bartlett JG, Doern GV (2001) A fresh look at the definition of susceptibility of Streptococcus pneumoniae to beta-lactam antibiotics. Arch Intern Med 161:2538-2544
32. Crnich CJ, Proctor RA (2004) Treatment of pneumococcal pneumonia: what's in an MIC? Crit Care Med 32:876-878. DOI 10.1097/01.CCM.0000114999.81252. B5
33. Lipman J, Wallis SC, Rickard CM, Fraenkel D (2001) Low cefpirome levels during twice-daily dosing in critically ill septic patients: pharmacokinetic modelling calls for more frequent dosing. Intensive Care Med 27:363-370
34. Craig WA (2004) Overview of newer antimicrobial formulations for overcoming pneumococcal resistance. Am J Med 117 [Suppl 3A]:16S-22S
35. Castanheira M, Gales AC, Mendes RE, Jones RN, Sader HS (2004) Antimicrobial susceptibility of Streptococcus pneumoniae in Latin America: results from 5 years of the SENTRY Antimicrobial Surveillance Program. Clin Microbiol Infect 10:645-651
36. Yu, Campbell GD Jr, Siberman R (1998) Drug-resistant Streptococcus pneumoniae. Clin Infect Dis 26:1188-1195
37. Reinert RR, Reinert S, van der Linden M, Cil MY, Al-Lahham A, Appelbaum P (2005) Antimicrobial susceptibility of Streptococcus pneumoniae in eight Luropean countries from 2001 to 2003. Antimicrob Agents Chemother 49:2903-2913. DOI 10.1128/AAC.49.7.2903-2913.2005
38. Pihlajamaki M, Jalava J, Huovinen P, Kotilainen P, Finnish Study Group for Antimicrobial Resistance (2003) Antimicrobial resistance of invasive pneumococci in Finland in 1999-2000. Antimicrob Agents Chemother 47:1832-1835. DOI 10.1128/AAC.47.6.1832-1835.2003
39. Feikin DR, Schuchat A, Kolczak M, Barrett NL, Harrison LH, Lefkowitz L, McGeer A, Farley MM, Vugia DJ, Lexau C, Stefonek KR, Patterson JL, Jorgensen JH (2000) Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health 90:223-229
40. National Committee for Clinical Laboratory Standards (2002) Performance standards for antimicrobial susceptibility testing. Twelfth informational supplement. Document M100-S12. National Committee for Clinical Laboratory Standards, Wayne, PA, USA
41. Yu VL, Chiou CC, Feldman C, Ortqvist A, Rello J, Morris AJ, Baddour LM, Luna CM, Snydman DR, Ip M, Ko WC, Chedid MB, Andremont A, Klugman KP, International Pneumococcal Study Group (2003) An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis 37:230-237
42. Song JH, Jung SI, Ki HK (2004) Clinical outcomes of pneumococcal pneumonia caused by antibioticresistant strains in Asian countries: a study by the Asian Network for Surveillance of Resistant Pathogens. Clin Infect Dis 38:1570-1578
43. National Committee for Clinical Laboratory Standards (1999) Performance standards for antimicrobial susceptibility testing. Ninth informational supplement. Document M100-S9. National Committee for Clinical Laboratory Standards, Wayne, PA, USA
44. Tleyjeh IM, Tlaygeh HM, Hejal R, Montori VM, Baddour LM (2006) The impact of penicillin resistance on short-term mortality in hospitalized adults with pneumococcal pneumonia: a systematic review and meta-analysis. Clin Infect Dis 42:788-797. DOI 10.1086/500140
45. Lonks JR, Garau J, Gomez L, Xercavins M, Ochoa de Echaguen A, Gareen IF, Reiss PT, Medeiros AA (2002) Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis 35:556-564
46. Van Kerkhoven D, Peetermans WE, Verbist L, Verhaegen J (2003) Break-through pneumococcal bacteraemia in patients treated with clarithromycin or oral beta-lactams. J Antimicrob Chemother 51:691-696
47. Mortensen EM, Restrepo MI, Anzueto A, Pugh J (2006) The impact of empiric antimicrobial therapy with a β-lactam and fluoroquinolone on mortality for patients hospitalized with severe pneumonia. Crit Care 10:R8. DOI 10.1186/cc3934
48. Canton R, Morosini M, Enright MC, Morrissey I (2003) Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone resistant Streptococcus pneumoniae: data from the global PROTEKT surveillance programme. J Antimicrob Chemother 52:944-952. DOI 10.1093/jac/dkg465
49. Davidson R, Cavalcanti R, Brunton JL (2002) Resistance to levofloxacin and failure of treatment of Pneumococcal Pneumonia. N Engl J Med 346:747-750
50. Rello J, Catalán M, Díaz E, Bodí M, Alvarez B (2002) Associations between empirical antimicrobial therapy at the hospital and mortality in patients with severe community-acquired pneumonia. Intensive Care Med 28:1030-1035. DOI 10.1007/s00134-002-1325-3
51. Mufson MA, Stanek RJ (1999) Bacteremic pneumococcal pneumonia in one American City: a 20-year longitudinal study, 1978-1997. Am J Med 107:34S-43S
52. Waterer G, Somes GW, Wunderink R (2001) Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 161:1837-1842
53. Harbarth S, Garbino J, Pugin J, Romand JA, Pittet D (2005) Lack of effect of combination antibiotic therapy on mortality in patients with pneumococcal sepsis. Eur J Clin Microbiol Infect Dis 24:688-690. DOI 10.1007/s10096-005-0018- 6
54. Finch R, Schurmann D, Collins O, Kubin R, McGivern J, Bobbaers H, Izquierdo JL, Nikolaides P, Ogundare F, Raz R, Zuck P, Hoeffken G (2002) Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Antimicrob Agents Chemother 46:1746-1754. DOI 10.1128/AAC.46.6.1746-1754.2002
55. Frank E, Liu J, Kinasewitz G, Moran GJ, Oross MP, Olson WH, Reichl V, Freitag S, Bahal N, Wiesinger BA, Tennenberg A, Kahn JB (2002) A multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia. Clin Ther 24:1292-1308
56. Sugiyama Y, Yanagisawa K, Tominaga SI, Kitamura S (1999) Effects of long-term administration of erythromycin on cytokine production in rat alveolar macrophages. Eur Respir J 14:1113-1116
57. Khan AA, Slifer TR, Araujo FG, Remington JS (1999) Effect of clarithromycin and azithromycin on production of cytokines by human monocytes. Int J Antimicrob Agents 11:121-132
58. Lieberman D, Schlaeffer F, Boldur I et al (1996) Multiple pathogens in adult patients admitted with community-acquired pneumonia: a 1 year prospective study of 346 consecutive patients. Thorax 51:179-184
59. Almirall J, Bolibar I, Vidal J et al (2000) Epidemiology of community-acquired pneumonia in adults: a population-based study. Eur Respir J 15:757-763
60. Waterer RW, Rello J (2006) Choosing the right combination therapy in severe community-acquired pneumonia. Crit Care 10:115-116. DOI 10.1186/cc3976
61. Shorr AF, Bodi M, Rodriguez A, Sole-Violan J, Garnacho-Montero J, Rello J (2006) Impact of antibiotic guideline compliance on duration of mechanical ventilation in critically ill patients with community-acquired pneumonia. ATS Conference, San Diego, May 2006
62. File TM jr, Tan JS, Boex JR (2006) The clinical relevance of penicillin-resistant Streptococcus pneumoniae: A new perspective. Clin Infect Dis 42:798-800. DOI 10.1086/500142